| LDR | | 00000nam u2200205 4500 |
| 001 | | 000000433067 |
| 005 | | 20200225111850 |
| 008 | | 200131s2019 ||||||||||||||||| ||eng d |
| 020 | |
▼a 9781687921987 |
| 035 | |
▼a (MiAaPQ)AAI22614956 |
| 040 | |
▼a MiAaPQ
▼c MiAaPQ
▼d 247004 |
| 082 | 0 |
▼a 616 |
| 100 | 1 |
▼a Shapovalova, Mariya. |
| 245 | 10 |
▼a Molecular Imaging of Prostate Cancer Using Biomarker-Guided Strategies. |
| 260 | |
▼a [S.l.]:
▼b University of Minnesota.,
▼c 2019. |
| 260 | 1 |
▼a Ann Arbor:
▼b ProQuest Dissertations & Theses,
▼c 2019. |
| 300 | |
▼a 139 p. |
| 500 | |
▼a Source: Dissertations Abstracts International, Volume: 81-04, Section: B. |
| 500 | |
▼a Advisor: LeBeau, Aaron. |
| 502 | 1 |
▼a Thesis (Ph.D.)--University of Minnesota, 2019. |
| 506 | |
▼a This item must not be sold to any third party vendors. |
| 506 | |
▼a This item must not be added to any third party search indexes. |
| 520 | |
▼a Prostate cancer affects 1 in 9 men in their lifetime. While disease that is detected early can be very treatable, recurrence affects about 30% of the patients. Imaging is an important tool for detecting and assessing therapeutic regimens for prostate cancer patients. Patients with advanced stages of prostate cancer, typically those who have had a recurrence and are forming resistance to hormone therapy, are in a great need for a more accurate assessment of the extent of their disease for a better understanding of its aggressiveness. Clinical imaging offers physicians information about the location and extent of disease. Unfortunately, conventional imaging methods often lack the sensitivity needed to detect some lesions properly, especially when the disease is no longer localized and has spread outside of the prostate, which leads to insufficient information that is needed for proper diagnosis and treatment planning. Most of the current imaging techniques are not specific for tumor physiological processes. Therefore, a clinical need remains for new imaging agents that can target prostate tumors more specifically and sensitively. My PhD research focused on using molecular-genetic imaging approaches to develop imaging agents in vitro and in vivo that can detect prostate cancer using the cancer's unique regulatory genetic differences from normal cells. I investigated the expression two prostate cancer-specific genes, AMACR and PEG10 and used the genes' unique transcriptional regulations in the prostate cancer cells to induce prostate cancer-specific expression of reporter proteins. Specifically, I used the promoters of AMACR and PEG10 in adenovirus and plasmid DNA vectors upstream of various reporter genes to induce expression of reporter proteins in prostate cancer cells. By using the prostate cancer-specific promoters, I was able to image prostate cancer in vivo using various vectors and different modes of imaging such as bioluminescence/fluorescence and positron emission tomography imaging. My results strongly support that prostate cancer specific promoters can induce prostate cancer specific gene expression and may have the potential to be used for imaging purposes. |
| 590 | |
▼a School code: 0130. |
| 650 | 4 |
▼a Oncology. |
| 650 | 4 |
▼a Medical imaging. |
| 690 | |
▼a 0992 |
| 690 | |
▼a 0574 |
| 710 | 20 |
▼a University of Minnesota.
▼b Pharmacology. |
| 773 | 0 |
▼t Dissertations Abstracts International
▼g 81-04B. |
| 773 | |
▼t Dissertation Abstract International |
| 790 | |
▼a 0130 |
| 791 | |
▼a Ph.D. |
| 792 | |
▼a 2019 |
| 793 | |
▼a English |
| 856 | 40 |
▼u http://www.riss.kr/pdu/ddodLink.do?id=T15493253
▼n KERIS
▼z 이 자료의 원문은 한국교육학술정보원에서 제공합니다. |
| 980 | |
▼a 202002
▼f 2020 |
| 990 | |
▼a ***1008102 |
| 991 | |
▼a E-BOOK |